Navigation Links
Two Antidepressants Given to Dementia Patients Ineffective: Study
Date:7/19/2011

By Alan Mozes
HealthDay Reporter

TUESDAY, July 19 (HealthDay News) -- The antidepressants most often prescribed to treat depression in dementia patients provide no appreciable relief, and may raise the risk for serious side effects, new British research suggests.

"The two classes of antidepressants most likely to be prescribed for depression in Alzheimer's disease are no more effective than placebo," the study authors said.

The drugs in question are Zoloft (sertraline), and Remeron (mirtazapine).

"In our study, there were more adverse reactions in individuals treated with antidepressants than there were with placebo," the research team added. "Clinicians and investigators need to reframe the way they think about the treatment of people with Alzheimer's disease who are depressed, and reconsider routine prescription of antidepressants."

Led by Sube Banerjee of the Institute of Psychiatry at Kings College London in England, the authors reported their findings online July 19 in The Lancet.

Banerjee and his colleagues focused on 325 patients being treated at any of nine health centers across England for probable or possible Alzheimer's disease. The patients were also subject to bouts of depression lasting at least a month, and all registered above a minimum threshold during dementia-related depression exams.

None had been prescribed antidepressants prior to the study launch, nor were any in a critical stage of depression involving suicidal thoughts.

The patients were divided into three 13-week treatment groups. One group received 150 milligrams (mg) a day of sertraline; a second group received 45 mg a day of mirtazapine; and a third took sugar pills (placebos).

After three months, the authors found no difference in the incidence of depression among the three groups. The lack of an apparent benefit attributable to either sertraline or mirtazapine continued almost 10 months after the study's start, according to a journal news release.

Also, while about a quarter of those given placebos experienced adverse reactions as a result of treatment, that figure rose to between 41 percent and 43 percent in the groups given an antidepressant. Such side effects were also more likely to be serious among the antidepressant recipients than among the placebo group.

Dr. Henry Brodaty, an aging and dementia specialist at the University of New South Wales in Sydney, Australia, and author of an accompanying journal editorial, said the trial "has underscored the need for clinicians to think about creative alternatives to drug treatment for management of depression in people with dementia." It is important to use evidence-based techniques and to work in partnership with family caregivers, he wrote in the news release.

More information

For more on dementia and depression, visit the Alzheimer's Society.

--Alan Mozes

SOURCE: July 19, 2011, The Lancet, news release


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
2. Common Painkillers May Blunt Antidepressants
3. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
4. U. Iowa study suggests antidepressants aid physical recovery in stroke
5. Study Hints at Link Between Antidepressants and Heart Trouble
6. Antidepressants linked to thicker arteries
7. Decrease in suicide not linked to newer antidepressants
8. Autism: Lack of evidence for antidepressants
9. Certain Popular Antidepressants Linked to Cataracts in Seniors
10. Antidepressants in pregnancy increase risk of miscarriage
11. Antidepressants May Improve Heart Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two Antidepressants Given to Dementia Patients Ineffective: Study  
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. ... Pro . This new addition to the Mirroring360 product family combines device screen ... , Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – ... but be heartened by the industry’s current surge. But another thing that unifies them ... At last they can simply, safely and effectively end their aroma anguish thanks ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/18/2017)...  Socionext Inc. and SOINN Inc. today announced ... which Socionext extracts and delivers biometrics data to ... results in reading ultrasound images from Socionext,s viewphii™ ... results will be introduced at Medtec Japan, held ... 4505 & 4507. In this initial ...
Breaking Medicine Technology: